Head lice are tiny insects that live on the scalp of human beings and skins of other mammals. Adult Head lice feed the blood from the human scalps and can survive 30 days on human scalps. These are mostly found in women and children. Head lice are transferred from one person to another due to direct contact. Head lice are characterized with symptoms such as intense itching, tingling feeling on movement of hair, and sores on the scalp, neck and shoulders. Head lice infestation is caused by poor personal hygiene. Head lice can be treated with over-the-counter medicines and prescribed medications.
Global Head Lice Drug Market: Drivers
There has been increasing burden of head lice in both rural and urban areas due to pollution and direct contact with large groups of people at schools, day care clinics, salons, etc. Moreover, according to the National Library of Medicine’s 2019 report, infestation of head lice in females is 50% and 3% in males globally. Furthermore, Lice Clinics of America, providing safety and urgent treatment of head lice and promoting the use of lice removal kits through digital campaign to curb the increasing prevalence of head lice in U.S.
Global Head Lice Drug Market: COVID-19 Impact Analysis
COVID-19 has affected several markets around the world. Furthermore, implementation of lockdown and restrictions placed on transportation by governments of various countries have affected supply chain activities, thus leading to shortage in inventories of pharmaceutical companies.
Global Head Lice Drug Market: Restraints
Head lice drugs are not always successful in eradicating head lice due to lack of patience in human patients because the treatment head lice takes longer period of time due to its reoccurrence. Moreover, greater efficiency in treatment of head lice requires constant combing regimes, which lead to discomfort in patients. These factors are expected to restrain growth of the global head lice drug market.
Global Head Lice Drug Market Regional Analysis
On basis of region, the global head lice drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, burden of head lice is higher in young children and women working in school. According to the National Library of Medicine’s 2016 report, infestation of head lice in children and women is 6 to 12 million in the U.S every year. Moreover, pharmaceutical companies are focusing on mergers and acquisitions to strengthen their share in the global head lice drug market. For instance, in 2017, Piedmont Pharmaceuticals received approval for RESULTZ Lice & Egg Elimination Kit, a head lice remover kit with isopropyl myristate, 50% cyclomethicone drug from the U.S Food Drug and Administration.
Pharmaceutical companies are focusing on mergers and acquisitions to strengthen their market share in global head lice drug market. For instance, in 2019, PIC Corporation entered an agreement with ICB Pharma, a European pharmaceutical company for exclusive licencing and distribution of Nitolic Head Lice and Nits Treatment Kit.
Global Head Lice Drug Market: Key Players
Key operating players in the global head lice drug market are Perrigo Company plc, Bayer AG, Prestige Consumer Healthcare, Stada Arzneimittel, Alliance Pharma Inc., Reckitt Benckiser Group plc/N.V, Arbor Pharmaceuticals, LLC, Cerecor Inc., Medexus Pharmaceuticals, Nuvo Pharmaceuticals, Piedmont Pharmaceuticals LLC, and ICB PHARMA.
On the basis of product type, the global head lice drug market is segmented into:
- Creams and Lotion
- Lice Removal Kits
On the basis of application, the global head lice drug market is segmented into:
On the basis of distribution channel, the global head lice drug market is segmented into:
- Hospitals Pharmacies
- Online Pharmacy
- Retail Pharmacy
On the basis of region, the global head lice drug market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East